Uri Aharon - RedHill Biopharma Insider

RDHL -- USA Stock  

USD 8.00  0.14  1.78%

  Executive
Mr. Uri Hananel Aharon serves as Chief Accounting Officer at Redhill Biopharma Ltd, effective since 2012. His work experience includes the following roles Team Manager at Ernst Young Israel and Accounting Intern at Ziv Haft, BDO . He holds a Bachelors degree in Accounting and Economics from The Hebrew University of Jerusalem and a MBA degree, majoring in Business Taxation, from the College of Management Academic Studies, Rishon LeZion.
Age: 35  Executive Since 2011  MBA    
972 3 541 3131  http://www.redhillbio.com
Aharon is a graduate of the Hebrew University and the Academic College for Management, Rishon Lezion .

Management Efficiency

The company has return on total asset (ROA) of (54.98) % which means that it has lost $54.98 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (98.45) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Haig BozigianNeurocrine Biosciences
2012
Christopher OBrienNeurocrine Biosciences
2007
Nuria BarnesGrifols S A
2015
Karen SmithJazz Pharmaceuticals Public Lim
2015
Malcolm LloydSmithNeurocrine Biosciences
2014
Raimon RouraGrifols S A
2017
Darin LippoldtNeurocrine Biosciences
2016
Dimitri GrigoriadisNeurocrine Biosciences
2007
Mark DehringCSL Limited
2014
Jane SorensenNeurocrine Biosciences
N/A
Julie CookeNeurocrine Biosciences
2017
Navjot RaiNeurocrine Biosciences
Montserrat CalvoGrifols S A
2017
Eric BenevichNeurocrine Biosciences
2015
Arvind SoodAmgen
2012
Bernard RonchiCSL Limited
2015
Miguel MontblanchGrifols S A
2017
John LevyCSL Limited
2017
Edward BaileyCSL Limited
2017
Fiona MeadCSL Limited
2018
Kyle GanoNeurocrine Biosciences
2016

Entity Summary

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel. RedHill Biopharma operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 74 people.RedHill Biopharma Ltd (RDHL) is traded on Nasdaq Capital Markets in USA. It is located in 21 Ha'arba'a Street and employs 74 people.

RedHill Biopharma Leadership Team

Patricia Anderson, Vice President - Regulatory Affairs
Micha Chorin, CFO
Ofer Tsimchi, Director
Patrick Mclean, Product Manager
Aida Bibliowicz, Vice President - Clinical Affairs Europe
Ori Shilo, Co-Founder and Deputy CEO of Fin. and Operations
Shmuel Cabilly, Director
Dror BenAsher, Chairman of the Board, CEO
Kenneth Reed, Director
Elkan Gamzu, Product Manager
Adi Frish, Sr. VP of Bus. Devel. and Licensing
Guy Goldberg, Chief Business Officer
Reza Fathi, Sr. VP of RandD
Tom Lang, Vice President - Regulatory & Clinical Affairs
Clara Fehrmann, Product Manager
Pascal Weerts, Director - Corporate and Legal Affairs
Eric Swenden, Director
Dan Suesskind, Director
Gilead Raday, Senior Vice President - Product and Corporate Development
Rick Scruggs, Director
Terry Plasse, Medical Director
Danielle Abramson, Director - Intellectual Property & Research
Uri Aharon, Chief Accounting Officer
Shani Maurice, Vice President - Business Development & Communications
Patricia Bandeira, Product Manager - Oncology
Ira Kalfus, Medical Director
Nurit Benjamini, External Director

Stock Performance Indicators

Current Sentiment - RDHL

RedHill Biopharma Investor Sentiment

Most of Macroaxis users are at this time bullish on RedHill Biopharma Ltd. What is your perspective on investing in RedHill Biopharma Ltd? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip
Currently Active Assets on Macroaxis
S   
Purchased over 400 shares of
few hours ago
Traded for 6.36
VMW   
Purchased a lot of shares of
few hours ago
Traded for 153.4
GOOG   
Purchased few shares of
few hours ago
Traded for 1161.22
TWTR   
Purchased over 100 shares of
few hours ago
Traded for 29.52
MSFT   
Purchased over 20 shares of
few hours ago
Traded for 111.7
Additionally take a look at Your Equity Center. Please also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Search macroaxis.com